Funding Momentum OneSkin has recently secured significant investment activity, including a $7M Series A in 2024 followed by a $20M Series A in 2025, signaling strong growth momentum and potential for scaled partnerships and co-development initiatives in skin longevity.

Product Platform The OS-01 peptide platform targets multiple aging pathways (skin barrier improvement, DNA repair support, and senescent cell management), presenting opportunities for premium skincare collaborations, contract manufacturing, or licensing deals with larger dermocosmetic brands seeking science-backed longevity solutions.

Clinical & Scientific Prestige Recognition such as Fast Company’s Most Innovative Companies List (2024) and ARDD sponsorships enhances credibility with dermatology clinics, research institutions, and high-end SKUs—ideal for partnerships with clinical testing programs, white-label products, or sponsored research ventures.

Growth Focus Recent investor backing and a growing product portfolio (OS-01 BODY and OS-01 EYE launches) indicate expansion into targeted channels and categories, presenting sales opportunities with specialty retailers, eye-area and body-care segments, and international distributors seeking innovative anti-aging solutions.

Industry Positioning Operating in a competitive longevity niche with notable peers, OneSkin can be approached for collaboration on joint marketing, co-branded campaigns, or distributor agreements that leverage its differentiated biology-backed narrative to accelerate market adoption.